Showing results (11-20 of 558) with videos related to
Sort By:
Pageof 56
Archives of Neurology|November 1, 1988
Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's diseaseB Dubois, B Pillon, F Legault, et al.Revue Neurologique|May 1, 1977
["Beginning and end of dose" dyskinesias caused by L-DOPA]F Lhermitte, Y Agid, J L Signoret, et al.Archives of Neurology|August 1, 1986
Disappearance of parkinsonian signs after spontaneous vascular 'thalamotomy'B Dubois, B Pillon, H De Saxce, et al.Revue Neurologique|January 1, 1985
[The L-dopa test in Parkinson's disease]M Esteguy, A M Bonnet, J Kefalos, et al.Lancet (London, England)|March 17, 1979
Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's diseaseY Agid, P Pollak, A M Bonnet, et al.Annals of Neurology|July 1, 1987
Cholinergic-dependent cognitive deficits in Parkinson's diseaseB Dubois, F Danzé, B Pillon, et al.Neurology|September 1, 1987
Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?A M Bonnet, Y Loria, M H Saint-Hilaire, et al.Journal of Neurology, Neurosurgery, and Psychiatry|February 1, 1989
Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?B Pillon, B Dubois, G Cusimano, et al.Journal of Affective Disorders|May 1, 1983
Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparisonR Jouvent, P Abensour, A M Bonnet, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 1, 1982
Confusion, dementia and anticholinergics in Parkinson's diseaseY de Smet, M Ruberg, M Serdaru, et al.Pageof 56